Skip to main content
. 2017 Apr 14;12(4):e0175826. doi: 10.1371/journal.pone.0175826

Fig 4. Patient concerns when first prescribed their treatment.

Fig 4

BioSN, Patient receiving biosimilar who was previously biologic-naïve; BioSE, Patient receiving biosimilar who has experience of a bio-originator; BioOA, Patient receiving bio-originator who was initiated after February 2015; BioOB, Patient receiving bio-originator who was initiated before January 2015. “Blue”- BioSN, “orange accent 6”- BioSE, “grey”- BioOA, “orange”—BioOB.